Cost-effectiveness Analysis of Selexipag for the Combined Treatment of Pulmonary Arterial Hypertension

Overview

Journal Front Pharmacol

Date 2023 Aug 28

PMID 37637431

Authors

Wenxing Dong

Zhe Zhang

Mingming Chu

Peng Gu

Min Hu

Lulu Liu

Jingbin Huang

Rong Zhang

Affiliations

Soon will be listed here.

Abstract

Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a considerably higher cost. This study evaluated the cost-effectiveness of adding selexipag to the combined treatment of ERA and PDE5i in patients with PAH from a Chinese healthcare system perspective. A Markov model was developed to assess costs and quality-adjusted life years (QALYs) of macitentan + tadalafil + selexipag vs. macitentan + tadalafil for the treatment of PAH. Markov states included WHO Functional Class (FC) (I-IV) and death. Transition probabilities were based on data from the TRITON trial. Mortality rates, costs, and utilities were obtained from published literature and public databases. In the base case analysis, compared with macitentan + tadalafil, selexipag + macitentan + tadalafil increased costs ($357,807.588 vs. $116,534.543, respectively) and QALYs (7.234 QALYs vs. 6.666 QALYs, respectively). The resulting incremental cost-effectiveness ratio was $424,746.070 per QALY, which was higher than the willingness-to-pay (WTP) of $38,223.339 per QALY. The results were most sensitive to HR for mortality of patients with FC IV relative to the general population, discount rate, and the cost of selexipag. The probability was greater than 50% for the selexipag + macitentan + tadalafil only if the WTP was more significant than $426,019.200 per QALY. In China, adding selexipag may not be cost-effective for patients with PAH who failed to control their condition after combined treatment of ERA and PDE5i. Results of the analysis can aid discussions on the value and position of selexipag for the combined treatment of PAH.

References

Zhai Z, Zhou X, Zhang S, Xie W, Wan J, Kuang T . The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey. Medicine (Baltimore). 2017; 96(39):e6783. PMC: 5626251. DOI: 10.1097/MD.0000000000006783. View

Ogbomo A, Tsang Y, Mallampati R, Panjabi S . The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. J Manag Care Spec Pharm. 2022; 28(6):608-616. PMC: 10372985. DOI: 10.18553/jmcp.2022.28.6.608. View

Leber L, Beaudet A, Muller A . Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021; 11(1):2045894020977300. PMC: 7797595. DOI: 10.1177/2045894020977300. View

Klinger J, Elliott C, Levine D, Bossone E, Duvall L, Fagan K . Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019; 155(3):565-586. DOI: 10.1016/j.chest.2018.11.030. View

Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs A, Carswell C . Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022; 25(1):10-31. DOI: 10.1016/j.jval.2021.10.008. View

Fleurence R, Hollenbeak C . Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2006; 25(1):3-6. DOI: 10.2165/00019053-200725010-00002. View

Simonneau G, Torbicki A, Hoeper M, Delcroix M, Karlocai K, Galie N . Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012; 40(4):874-80. DOI: 10.1183/09031936.00137511. View

Zhang R, Dai L, Xie W, Yu Z, Wu B, Pan L . Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011; 140(2):301-309. DOI: 10.1378/chest.10-2327. View

Hassoun P . Pulmonary Arterial Hypertension. N Engl J Med. 2021; 385(25):2361-2376. DOI: 10.1056/NEJMra2000348. View

10.

Thongsri W, Bussabawalai T, Leelahavarong P, Wanitkun S, Durongpisitkul K, Chaikledkaew U . Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2015; 16(4):525-36. DOI: 10.1586/14737167.2016.1120672. View

11.

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. View

12.

Liu J, Cao L, Wu J . Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. Front Public Health. 2022; 10:987408. PMC: 9521600. DOI: 10.3389/fpubh.2022.987408. View

13.

Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs A, Carswell C . Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022; 376:e067975. PMC: 8749494. DOI: 10.1136/bmj-2021-067975. View

14.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

15.

Chin K, Sitbon O, Doelberg M, Feldman J, Gibbs J, Grunig E . Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021; 78(14):1393-1403. DOI: 10.1016/j.jacc.2021.07.057. View

16.

Ruopp N, Cockrill B . Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022; 327(14):1379-1391. DOI: 10.1001/jama.2022.4402. View

17.

Keogh A, McNeil K, Wlodarczyk J, Gabbay E, Williams T . Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant. 2007; 26(2):181-7. DOI: 10.1016/j.healun.2006.11.009. View

18.

Fuge J, Park D, von Lengerke T, Richter M, Gall H, Ghofrani H . Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study. Front Psychiatry. 2022; 12:781532. PMC: 8861193. DOI: 10.3389/fpsyt.2021.781532. View

19.

Coyle K, Coyle D, Blouin J, Lee K, Jabr M, Tran K . Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study. Pharmacoeconomics. 2016; 34(5):509-20. PMC: 4828471. DOI: 10.1007/s40273-015-0366-8. View

20.

Galie N, Barbera J, Frost A, Ghofrani H, Hoeper M, McLaughlin V . Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(9):834-44. DOI: 10.1056/NEJMoa1413687. View